Experimental drug shows promise against hard-to-treat lung and pancreatic cancers
An experimental cancer drug called ERAS-0015 has shown it is safe and can shrink tumors in patients with lung and pancreatic cancer, according to early trial results presented at a medical symposium in Barcelona. The drug targets cancers driven by mutations in the RAS gene, which were previously thought impossible to treat with medication.
The AURORAS-1 Phase I trial involved 148 patients who had already tried other cancer treatments. According to the European Organisation for Research and Treatment of Cancer, ERAS-0015 caused tumors to shrink significantly in 44% of patients with RAS-mutant pancreatic cancer and 60% of patients with RAS-mutant lung cancer.
The drug works as a "pan-RAS molecular glue," meaning it brings proteins together in a way that blocks growth signals from several different RAS mutations. RAS mutations act like switches stuck in the "on" position, continuously sending signals that fuel cancer. ERAS-0015 is designed to bind to these switches and stop those signals.
Medical oncologist Dr. Judy Wang told the symposium that ERAS-0015 was well tolerated with few severe side effects. The results are significant because patients with RAS-mutant cancers have had few or no treatment options available.
What it means in Raleigh
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.
